Nanotechnology for protein delivery: Overview and perspectives

被引:301
作者
Yu, Mikyung [1 ]
Wu, Jun [1 ]
Shi, Jinjun [1 ]
Farokhzad, Omid C. [1 ,2 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Anesthesiol, Lab Nanomed & Biomat, Boston, MA 02115 USA
[2] King Abdulaziz Univ, Jeddah, Saudi Arabia
基金
新加坡国家研究基金会; 美国国家卫生研究院;
关键词
Nanotechnology; Nanoparticle; Protein delivery; Therapy; Non-invasive administration; VIRUS-LIKE PARTICLES; CELL PENETRATING PEPTIDES; DRUG-DELIVERY; INTRACELLULAR DELIVERY; INSULIN DELIVERY; ORAL DELIVERY; FC-FUSION; NEURODEGENERATIVE DISEASES; PHARMACEUTICAL CARRIERS; TARGETED NANOPARTICLES;
D O I
10.1016/j.jconrel.2015.10.012
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Protein-based therapeutics havemade a significant impact in the treatment of a variety of important human diseases. However, given their intrinsically vulnerable structure and susceptibility to enzymatic degradation, many therapeutic proteins such as enzymes, growth factors, hormones, and cytokines suffer from poor physicochemical/biological stability and immunogenicity that may limit their potential benefits, and in some cases limit their utility. Furthermore, when protein therapeutics are developed for intracellular targets, their internalization and biological activity may be limited by inefficient membrane permeability and/or endosomal escape. Development of effective protein delivery strategies is therefore essential to further enhance therapeutic outcomes to enable widespread medical applications. This review discusses the advantages and limitations of marketed and developmental-stage protein delivery strategies, and provides a focused overview of recent advances in nanotechnology platforms for the systemic delivery of therapeutic proteins. In addition, we also highlight nanoparticle-mediated non-invasive administration approaches (e.g., oral, nasal, pulmonary, and transdermal routes) for protein delivery. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:24 / 37
页数:14
相关论文
共 137 条
  • [1] A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
    Akinc, Akin
    Zumbuehl, Andreas
    Goldberg, Michael
    Leshchiner, Elizaveta S.
    Busini, Valentina
    Hossain, Naushad
    Bacallado, Sergio A.
    Nguyen, David N.
    Fuller, Jason
    Alvarez, Rene
    Borodovsky, Anna
    Borland, Todd
    Constien, Rainer
    de Fougerolles, Antonin
    Dorkin, J. Robert
    Jayaprakash, K. Narayanannair
    Jayaraman, Muthusamy
    John, Matthias
    Koteliansky, Victor
    Manoharan, Muthiah
    Nechev, Lubomir
    Qin, June
    Racie, Timothy
    Raitcheva, Denitza
    Rajeev, Kallanthottathil G.
    Sah, Dinah W. Y.
    Soutschek, Juergen
    Toudjarska, Ivanka
    Vornlocher, Hans-Peter
    Zimmermann, Tracy S.
    Langer, Robert
    Anderson, Daniel G.
    [J]. NATURE BIOTECHNOLOGY, 2008, 26 (05) : 561 - 569
  • [2] Chitosan-based delivery systems for protein therapeutics and antigens
    Amidi, Maryam
    Mastrobattista, Enrico
    Jiskoot, Wim
    Hennink, Wim E.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2010, 62 (01) : 59 - 82
  • [3] Detection of weak receptor-ligand interactions using IgM and J-chain-based fusion proteins
    Ammann, Johannes U.
    Jahnke, Martin
    Dyson, Michael R.
    Kaufman, Jim
    Trowsdale, John
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (05) : 1354 - 1356
  • [4] [Anonymous], 2016, BOX SEA PAVING WAY F
  • [5] Magnetic nanoparticles for drug delivery
    Arruebo, Manuel
    Fernandez-Pacheco, Rodrigo
    Ibarra, M. Ricardo
    Santamaria, Jesus
    [J]. NANO TODAY, 2007, 2 (03) : 22 - 32
  • [6] Targeting FcαRI on Polymorphonuclear Cells Induces Tumor Cell Killing through Autophagy
    Bakema, Jantine E.
    Ganzevles, Sonja H.
    Fluitsma, Donna M.
    Schilham, Marco W.
    Beelen, Robert H. J.
    Valerius, Thomas
    Lohse, Stefan
    Glennie, Martin J.
    Medema, Jan Paul
    van Egmond, Marjolein
    [J]. JOURNAL OF IMMUNOLOGY, 2011, 187 (02) : 726 - 732
  • [7] Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Batchelor, Tracy T.
    Gerstner, Elizabeth R.
    Emblem, Kyrre E.
    Duda, Dan G.
    Kalpathy-Cramer, Jayashree
    Snuderl, Matija
    Ancukiewicz, Marek
    Polaskova, Pavlina
    Pinho, Marco C.
    Jennings, Dominique
    Plotkin, Scott R.
    Chi, Andrew S.
    Eichler, April F.
    Dietrich, Jorg
    Hochberg, Fred H.
    Lu-Emerson, Christine
    Iafrate, A. John
    Ivy, S. Percy
    Rosen, Bruce R.
    Loeffler, Jay S.
    Wen, Patrick Y.
    Sorensen, A. Greg
    Jain, Rakesh K.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (47) : 19059 - 19064
  • [8] Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
    Bertrand, Nicolas
    Wu, Jun
    Xu, Xiaoyang
    Kamaly, Nazila
    Farokhzad, Omid C.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2014, 66 : 2 - 25
  • [9] Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway
    Bitonti, AJ
    Dumont, JA
    Low, SC
    Peters, RT
    Kropp, KE
    Palombella, VJ
    Stattel, JM
    Lu, YC
    Tan, CA
    Song, JJ
    Garcia, AM
    Simister, NE
    Spiekermann, GM
    Lencer, WI
    Blumberg, RS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (26) : 9763 - 9768
  • [10] Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune Diseases
    Bluestone, Jeffrey A.
    Bour-Jordan, Helene
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2012, 4 (11):